Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model
fiercehealthcare - Teladoc Health reported better-than-expected fourth quarter financial results with both revenue and earnings exceeding analysts' expectations, driving a 15% jump in the company's stock Thursday.
AI Summary: Telehealth provider Teladoc reported slower growth and issued a cautious outlook as it shifts its telehealth model, warning of membership headwinds and potential declines in integrated‑care enrollment tied to market dynamics and policy changes. Management signaled strategic recalibration to stabilize long‑term performance.
CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health
fiercehealthcare - Elevance Health Chief Financial Officer Mark Kaye will grow his list of duties to include oversight of Carelon, the company announced Thursday.
AI Summary: Elevance Health elevated CFO Mark Kaye to take expanded responsibility overseeing Carelon as part of a broader C-suite reshuffle. The reorganization centralizes oversight of the company’s growth arm and signals a tighter alignment between payer operations and its care-management business amid strategic and operational realignments.
Novartis to build $23B radioligand therapy site
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.
UHS posts 11.5% operating margin in 2025 as net income jumps 30%
Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …
AI Summary: Universal Health Services reported robust 2025 financial results and outlined an optimistic 2026 outlook, driven by acute and behavioral health operations. Leadership flagged growth targets for admissions and behavioral services even as staffing and regulatory pressures persist — the usual blend of confidence and contingency planning.